FIELD: medicine.
SUBSTANCE: invention refers to treating cancer or metastasis in a subject. A method of treating melanoma or metastasis thereof in a subject comprises administering a composition comprising a thymosin-alpha peptide and a programmed cell death-1 (PD-1) inhibitor, wherein thymosin-alpha peptide is administered to said subject in a dosage within range of 0.1 to 10 mg/day, wherein the PD-1 inhibitor is administered to said subject in a dosage within range of 0.1 to 10 mg/kg.
EFFECT: invention provides a synergetic effect of combined use of thymosin-alpha and PD-1 in treating melanoma.
22 cl, 23 dwg, 6 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NOVEL APPROACH TO CANCER TREATMENT USING IMMUNOMODULATION | 2016 |
|
RU2817047C2 |
| USE OF THE PLINABULIN IN COMBINATION WITH THE IMMUNE RESPONSE CONTROL POINT INHIBITORS | 2016 |
|
RU2723021C2 |
| NEW APPROACH TO TREATING CANCER WITH APPLICATION OF IMMUNOMODULATION | 2016 |
|
RU2711380C2 |
| METHODS FOR TREATING CANCER, INCLUDING TIGIT-BINDING AGENTS | 2017 |
|
RU2765410C2 |
| MODULAR PARTICLES FOR IMMUNOTHERAPY | 2014 |
|
RU2672055C2 |
| METHOD FOR REDUCING MULTI-DRUG RESISTANCE WITH USING INOSITOL TRIPYROPHOSPHATE | 2010 |
|
RU2563127C2 |
| COMPOSITIONS CONTAINING TUCARESOL OR ANALOGUES THEREOF | 2017 |
|
RU2753543C1 |
| IL-10/FC FUSION PROTEINS SUITABLE AS IMMUNOTHERAPY ENHANCERS | 2020 |
|
RU2825306C1 |
| ANTICANCER AGENT CONTAINING LK8 PROTEIN AS ACTIVE INGREDIENT | 2004 |
|
RU2306147C2 |
| PHARMACEUTICAL COMPOSITION FOR ENHANCING ANTITUMOR EFFECT OF IMMUNE CHECKPOINT INHIBITOR | 2018 |
|
RU2760132C1 |
